We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Antiphospholipid Syndrome Collaborative Registry (APSCORE) (APSCORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00076713
Recruitment Status : Completed
First Posted : February 3, 2004
Last Update Posted : February 12, 2013
Information provided by (Responsible Party):

February 2, 2004
February 3, 2004
February 12, 2013
April 2000
April 2007   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00076713 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Antiphospholipid Syndrome Collaborative Registry (APSCORE)

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.

The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Serum, plasma, genomic DNA
Non-Probability Sample
Specialty and subspecialty clinics
Antiphospholipid Syndrome
Not Provided
Not Provided
Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003 Nov;48(11):3004-8. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2007
April 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Antiphospholipid antibodies with or without associated clinical manifestations
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
N01AR002248-000 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Robert Roubey, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institute on Minority Health and Health Disparities (NIMHD)
Not Provided
University of North Carolina, Chapel Hill
February 2013